{
  "title": "Using large language models for safety-related table summarization in clinical study reports",
  "url": "https://openalex.org/W4399161615",
  "year": 2024,
  "authors": [
    {
      "id": "https://openalex.org/A2114464026",
      "name": "Rogier Landman",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A2019639175",
      "name": "Sean P. Healey",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A5056090011",
      "name": "Vittorio Loprinzo",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A5098941268",
      "name": "Ulrike Kochendoerfer",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A4226894320",
      "name": "Angela Russell Winnier",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A2018243180",
      "name": "Peter V. Henstock",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A2113252651",
      "name": "Wenyi Lin",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A5111215720",
      "name": "Aqiu Chen",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A5104259749",
      "name": "Arthi Rajendran",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A5098941265",
      "name": "Sushant Penshanwar",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A2124158862",
      "name": "Sheraz Khan",
      "affiliations": [
        "Pfizer (United States)"
      ]
    },
    {
      "id": "https://openalex.org/A2131233460",
      "name": "Subha Madhavan",
      "affiliations": [
        "Pfizer (United States)"
      ]
    }
  ],
  "references": [
    "https://openalex.org/W2744633029",
    "https://openalex.org/W2721901041",
    "https://openalex.org/W6848024612",
    "https://openalex.org/W6849369673",
    "https://openalex.org/W4319460874",
    "https://openalex.org/W3003514020",
    "https://openalex.org/W6852654206",
    "https://openalex.org/W6851175542",
    "https://openalex.org/W6850995887",
    "https://openalex.org/W6855591165",
    "https://openalex.org/W6852173445",
    "https://openalex.org/W6781031682",
    "https://openalex.org/W6810593605",
    "https://openalex.org/W6846800256",
    "https://openalex.org/W6779884424",
    "https://openalex.org/W4385430086",
    "https://openalex.org/W4310419543",
    "https://openalex.org/W4388007786",
    "https://openalex.org/W4319662928",
    "https://openalex.org/W4322622443",
    "https://openalex.org/W4365511667",
    "https://openalex.org/W4353015365",
    "https://openalex.org/W4313451803",
    "https://openalex.org/W3046375318",
    "https://openalex.org/W4376874793",
    "https://openalex.org/W2171313960",
    "https://openalex.org/W4375850424",
    "https://openalex.org/W4385728371",
    "https://openalex.org/W3037979089"
  ],
  "abstract": "Abstract Objectives The generation of structured documents for clinical trials is a promising application of large language models (LLMs). We share opportunities, insights, and challenges from a competitive challenge that used LLMs for automating clinical trial documentation. Materials and Methods As part of a challenge initiated by Pfizer (organizer), several teams (participant) created a pilot for generating summaries of safety tables for clinical study reports (CSRs). Our evaluation framework used automated metrics and expert reviews to assess the quality of AI-generated documents. Results The comparative analysis revealed differences in performance across solutions, particularly in factual accuracy and lean writing. Most participants employed prompt engineering with generative pre-trained transformer (GPT) models. Discussion We discuss areas for improvement, including better ingestion of tables, addition of context and fine-tuning. Conclusion The challenge results demonstrate the potential of LLMs in automating table summarization in CSRs while also revealing the importance of human involvement and continued research to optimize this technology.",
  "full_text": null,
  "topic": "Automatic summarization",
  "concepts": [
    {
      "name": "Automatic summarization",
      "score": 0.8043229579925537
    },
    {
      "name": "Documentation",
      "score": 0.722303032875061
    },
    {
      "name": "Computer science",
      "score": 0.624616265296936
    },
    {
      "name": "Table (database)",
      "score": 0.5158752202987671
    },
    {
      "name": "Context (archaeology)",
      "score": 0.46344780921936035
    },
    {
      "name": "Quality (philosophy)",
      "score": 0.431709349155426
    },
    {
      "name": "Natural language processing",
      "score": 0.39120447635650635
    },
    {
      "name": "Artificial intelligence",
      "score": 0.3539867401123047
    },
    {
      "name": "Data science",
      "score": 0.34106600284576416
    },
    {
      "name": "Data mining",
      "score": 0.2501029372215271
    },
    {
      "name": "Paleontology",
      "score": 0.0
    },
    {
      "name": "Epistemology",
      "score": 0.0
    },
    {
      "name": "Programming language",
      "score": 0.0
    },
    {
      "name": "Philosophy",
      "score": 0.0
    },
    {
      "name": "Biology",
      "score": 0.0
    }
  ],
  "institutions": [
    {
      "id": "https://openalex.org/I180857899",
      "name": "Pfizer (United States)",
      "country": "US"
    }
  ],
  "cited_by": 10
}